Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera, Inc. (NASDAQ: NTRA) has announced the appointment of Dr. Alexey Aleshin as General Manager of Early Cancer Detection (ECD), part of its strategic expansion into the ECD market. Dr. Aleshin, who has extensive experience in oncology, will continue overseeing medical affairs while leading ECD initiatives. The company aims to leverage a biobank of colorectal cancer samples from Aarhus University, potentially accelerating ECD product development and FDA approval. CEO Steve Chapman emphasizes the opportunity to improve early cancer detection, enhancing patient outcomes.
Austin, Texas-based Natera, a leader in personalized genetic testing, announced a live presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. PT. CEO Steve Chapman and CFO Mike Brophy will discuss recent business activities and Natera's growth plans in the genetic testing industry. The presentation will address its impact on critical health decisions. Interested parties can access the live webcast and the archived presentation on investor.natera.com.
Natera, Inc. (NASDAQ: NTRA) presented key findings at the 2021 San Antonio Breast Cancer Symposium highlighting the use of its Signatera test in high-risk breast cancer patients. The studies indicated that detecting circulating tumor DNA (ctDNA) both pre- and post-surgery was crucial in predicting disease relapse, with ctDNA status being the strongest predictor of patient outcomes. As a custom-built test for monitoring cancer treatment, Signatera has shown significant potential in clinical settings for improving patient care and optimizing treatment strategies.
Natera, Inc. (NASDAQ: NTRA) announced the acceptance of the first manuscript from its groundbreaking SMART study for publication in the American Journal of Obstetrics and Gynecology. This study validates the Panorama non-invasive prenatal test (NIPT) for common trisomies, confirming its 99% sensitivity and >99.5% specificity for trisomy 21. The SMART study, involving over 20,000 patients, utilized an advanced AI algorithm, Panorama AI, which lowered the no-call rate to 1.5%. This research enhances the confidence of physicians in screening for genetic disorders during pregnancy.
Natera announced that the CMS has issued a final local coverage determination for pan-cancer immunotherapy monitoring using its Signatera molecular residual disease test. This coverage applies to Medicare patients undergoing immunotherapy, significantly expanding access to personalized monitoring. The Signatera test has shown high predictive accuracy in identifying non-responders early in treatment, aiming to improve cancer care outcomes. Natera sees this development as a crucial step in enhancing treatment decisions across various tumor types.
Natera, Inc. (NASDAQ: NTRA) reported a strong third quarter for 2021, achieving $158.1 million in total revenues, a 61.1% increase year-over-year. Product revenues rose to $150.7 million, driven by a 55.4% increase in processed tests, totaling 407,300. Despite a net loss of $151.3 million or ($1.63) per diluted share, the company raised its 2021 revenue guidance to $615-$625 million. Significant advancements include an exclusive biobank license and positive results from the Trifecta Study in kidney transplant.
Natera, Inc. (NASDAQ: NTRA) announced initial results from the Trifecta study, the largest biopsy-matched evaluation of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients. The study analyzed over 300 biopsy-matched samples, revealing that the Prospera test with quantification demonstrated an AUC of 0.81 for rejection detection, improving to 0.91 when differentiating rejection from quiescence. Natera anticipates publishing comprehensive results in early 2022, reinforcing its leadership in cfDNA technology.
Natera, Inc. (NASDAQ: NTRA) will announce its third-quarter 2021 financial results on November 4, 2021, after market close. A conference call to discuss these results, along with business activities and financial outlook, will take place at 1:30 p.m. PT (4:30 p.m. ET). Investors can join the call via live dial-in or webcast, with options for domestic and international participants. A replay of the webcast will be available later at investor.natera.com.
Natera, Inc. (NASDAQ: NTRA) has launched the Prospera Lung test, expanding its organ health offerings to include lung transplant assessments. Validated in the VALID study, this non-invasive test achieves a negative predictive value of 97.33% and 89.06% sensitivity, distinguishing between stable patients and acute rejection effectively. Natera also announced two new studies to compare Prospera against traditional biopsy methods. The company aims to improve patient outcomes among lung transplant recipients, addressing a significant clinical need for accurate monitoring.
